We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

80 hedge funds and large institutions have $39.7M invested in Cue Biopharma in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

632% more call options, than puts

Call options by funds: $769K | Put options by funds: $105K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

25% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 20

24% more capital invested

Capital invested by funds: $32.1M → $39.7M (+$7.59M)

7% more funds holding

Funds holding: 75 → 80 (+5)

0.07% more ownership

Funds ownership: 1.04% → 1.11% (+0.07%)

Holders
80
Holders Change
+5
Holders Change %
+6.67%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
25
Reduced
20
Closed
6
Calls
$769K
Puts
$105K
Net Calls
+$664K
Net Calls Change
+$522K

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$2.38M
2
BlackRock
BlackRock
New York
+$500K
3
Morgan Stanley
Morgan Stanley
New York
+$488K
4
Bank of America
Bank of America
North Carolina
+$185K
5
Jane Street
Jane Street
New York
+$130K

Top Sellers

Rank Fund Capital Flow
1
SMH
Sanders Morris Harris
Texas
-$713K
2
SPC
Sigma Planning Corp
Michigan
-$324K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$259K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$140K
5
Wells Fargo
Wells Fargo
California
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$154K +$93.4K +1,307 +205%
CIC
27
Cornercap Investment Counsel
Georgia
$153K – – –
Barclays
28
Barclays
United Kingdom
$147K +$104K +1,451 +363%
Jane Street
29
Jane Street
New York
$144K +$130K +1,821 New
Citadel Advisors
30
Citadel Advisors
Florida
$134K -$115K -1,613 -49%
Squarepoint
31
Squarepoint
New York
$115K +$58.9K +824 +131%
OQS
32
Occudo Quantitative Strategies
Florida
$88.3K +$79.7K +1,115 New
BAAM
33
Baker Avenue Asset Management
California
$85.5K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$83.8K +$786 +11 +1%
Deutsche Bank
35
Deutsche Bank
Germany
$78.7K +$65.4K +915 +1,173%
Wells Fargo
36
Wells Fargo
California
$77.7K -$116K -1,625 -62%
NCM
37
Nantahala Capital Management
Connecticut
$70.5K -$143 -2 -0.2%
NL
38
Navalign LLC
California
$66K +$59.6K +833 New
JP Morgan Chase
39
JP Morgan Chase
New York
$59.2K – – –
Cambridge Investment Research Advisors
40
Cambridge Investment Research Advisors
Iowa
$59K – – –
AQR Capital Management
41
AQR Capital Management
Connecticut
$59K -$3.65K -51 -6%
WPC
42
Wedmont Private Capital
Pennsylvania
$57.2K – – –
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$49K +$3.79K +53 +10%
AIG
44
American International Group
New York
$47.2K +$1.5K +21 +4%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$44.2K -$11.9K -166 -23%
Invesco
46
Invesco
Georgia
$40.5K -$5.5K -77 -13%
XT
47
XTX Topco
Cayman Islands
$40.4K -$90.5K -1,266 -71%
VOYA Investment Management
48
VOYA Investment Management
Georgia
$38.4K – – –
GCP
49
GSA Capital Partners
United Kingdom
$37K +$33.2K +465 New
CM
50
Caption Management
Oklahoma
$37K – – –
1
2
3 4

CUE Hedge Fund Activity: Q4 2023 in Review

80 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2023, worth a combined $39.7M — up 24% from $32.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 6 closed out — a net gain of 5 holders — while 25 added to existing stakes and 20 trimmed.

The largest buyer was Bleichroeder LP, adding an estimated $2.38M. The largest seller was Sanders Morris Harris, exiting entirely with an estimated $713K sold.

  • 80 institutional investors held Cue Biopharma (CUE) as of Q4 2023, up from 75 in Q3 2023.
  • Funds reported $39.7M of Cue Biopharma stock for Q4 2023, up 24% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q4 2023 and 6 closed out, a net change of +5 holders.
  • The largest Cue Biopharma buyer in Q4 2023 was Bleichroeder LP, an estimated $2.38M added.
  • The largest Cue Biopharma seller in Q4 2023 was Sanders Morris Harris, an estimated $713K sold.

Based on aggregated 13F filings for Q4 2023.